Clinical Trial Update: Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating vaccine therapy with or without interleukin-2 in metastatic melanoma (stage IV/recurrent) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Vaccine therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IV Melanoma, Recurrent Melanoma | Phase 2 | Status: COMPLETED